Envista (NASDAQ:NVST) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Envista (NASDAQ:NVST) from a hold rating to a sell rating in a research report released on Tuesday, Zacks.com reports.

According to Zacks, “Envista Holdings Corporation manufactures and sells dental products primarily in the United States and internationally. The company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics and dental eye loupes to oral surgeons, prosthodontists and periodontists; Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products. Envista Holdings Corporation is based in Brea, California. “

A number of other equities analysts also recently issued reports on the company. Credit Suisse Group dropped their price target on Envista from $23.00 to $21.00 and set a neutral rating on the stock in a research report on Wednesday, May 13th. Bank of America increased their price target on Envista from $21.50 to $23.00 and gave the stock a neutral rating in a research report on Monday, July 20th. Robert W. Baird dropped their price target on Envista from $25.00 to $23.00 and set an outperform rating on the stock in a research report on Wednesday, May 13th. Piper Sandler increased their price target on Envista from $20.00 to $22.00 and gave the stock a neutral rating in a research report on Friday, July 31st. Finally, Morgan Stanley upped their price objective on Envista from $18.00 to $24.00 and gave the stock an equal weight rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. Envista presently has a consensus rating of Buy and a consensus price target of $27.82.

Shares of Envista stock opened at $22.73 on Tuesday. The stock’s fifty day moving average is $22.10 and its two-hundred day moving average is $20.84. Envista has a 52 week low of $10.08 and a 52 week high of $33.30.

Envista (NASDAQ:NVST) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.14. The business had revenue of $362.00 million during the quarter, compared to the consensus estimate of $346.33 million.

A number of institutional investors have recently added to or reduced their stakes in the business. Psagot Investment House Ltd. grew its holdings in Envista by 23.8% in the second quarter. Psagot Investment House Ltd. now owns 2,653 shares of the company’s stock valued at $56,000 after purchasing an additional 510 shares during the period. Arizona State Retirement System grew its holdings in Envista by 1.6% in the second quarter. Arizona State Retirement System now owns 35,932 shares of the company’s stock valued at $758,000 after purchasing an additional 549 shares during the period. Parkside Financial Bank & Trust grew its holdings in Envista by 89.8% in the first quarter. Parkside Financial Bank & Trust now owns 2,118 shares of the company’s stock valued at $32,000 after purchasing an additional 1,002 shares during the period. Comerica Bank grew its holdings in Envista by 0.9% in the second quarter. Comerica Bank now owns 124,291 shares of the company’s stock valued at $2,775,000 after purchasing an additional 1,054 shares during the period. Finally, State of Wisconsin Investment Board grew its holdings in Envista by 0.6% in the second quarter. State of Wisconsin Investment Board now owns 238,860 shares of the company’s stock valued at $5,038,000 after purchasing an additional 1,450 shares during the period.

About Envista

Envista Holdings Corporation manufactures and sells dental products in the United States and internationally. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands.

See Also: What sectors are represented in the Nikkei Index?

Get a free copy of the Zacks research report on Envista (NVST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Envista (NASDAQ:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply